As of 4:00pm ET
| -0.70 / -0.41%|
Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. Its products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
|Robert A. Bradway||Chairman & Chief Executive Officer|
|Esteban Santos||Executive Vice President-Operations|
|David W. Meline||Chief Financial Officer & Executive Vice President|
|Paul R. Eisenberg||Chief Medical Officer & Senior VP-Global Medical|
|Cynthia M. Patton||Chief Compliance Officer & Senior Vice President|